BiotechTube
Innovative Cellular Therapeutics

Innovative Cellular Therapeutics

Rockville, United States· Est.
ictbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Innovative Cellular Therapeutics is a clinical-stage biotech pioneering CAR-T therapies for solid tumors, a significant unmet medical need. The company's core asset is its proprietary CoupledCAR® platform, which underpins its lead program, GCC19CART, for metastatic colorectal cancer, showing promising early clinical response rates. ICT has built a multi-platform technology suite including INSTACAR™ and ARMOREDCAR™ to support the development of enhanced cellular immunotherapies. As a private company, it is advancing a pipeline focused on translating its platform technologies into potential first-in-class treatments for challenging cancers.

Oncology

Technology Platform

CoupledCAR®: Proprietary immunotherapy platform for solid tumor CAR-T R&D. ARMOREDCAR™: Engineering framework for cytokine modulation and TME resilience. INSTACAR™: Integrated platform for cryopreservation, R&D, and diagnostic services.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The successful development of GCC19CART could address a major unmet need in metastatic colorectal cancer, representing a multi-billion dollar market opportunity as a potential first-in-class therapy.
Furthermore, validation of its CoupledCAR® and ARMOREDCAR™ platforms would enable rapid expansion into other high-prevalence solid tumors, such as prostate and pancreatic cancers, creating a broad and valuable pipeline.

Risk Factors

Key risks include clinical failure or emergence of significant safety issues in ongoing and future trials for GCC19CART, which is in early-stage development.
The company also faces intense competition in the solid tumor CAR-T space, technological obsolescence, and the financial risks associated with being a pre-revenue, private company dependent on external funding.

Competitive Landscape

ICT operates in the highly competitive field of solid tumor CAR-T therapy, competing with numerous well-funded biotechs (e.g., Adaptimmune, TCR2 Therapeutics, Instil Bio) and large pharma companies (e.g., Gilead, Novartis, Bristol Myers Squibb) developing their own platforms. Differentiation hinges on the efficacy, safety, and technological advantages of its CoupledCAR® and ARMOREDCAR™ platforms.

More companies in United States →